Project title: Enhancing peptide receptor radionuclide therapy in well-differentiated pancreatic NETs
Brian R. Untch, MD Memorial Sloan Kettering Cancer Center
- Status: Completed
- Year(s): 2017
- Grant Type: Collaborative
- Research Type: Basic
- Primary Tumor Site: Pancreas
- Area of Inquiry: Models
- Article/Video: Click Here
- Also seen in November 2017 eUpdate
General Description
Well-differentiated neuroendocrine tumors (NETs) express high levels of the transmembrane somatostatin receptor subtype 2 (sstr2). Diagnostic and therapeutic radionuclides targeting this receptor have been successful in the clinic, resulting in the FDA-approval of 68Ga-DOTA-TATE for NET imaging and the pending application of peptide receptor radiotherapy (PRRT) 177Lu-DOTA-TATE for treatment of advanced disease. We have utilized a pre-clinical murine model of well-differentiated pancreatic neuroendocrine tumor (PanNET) to study SSTR2-based radionuclide imaging and therapy. The Pdx1-Cre, Men1f/f mouse model was previously characterized and produces a spectrum of islet cell phenotypes from hyperplasia to neoplasia. Using this model, we documented SSTR2 membrane expression in neoplastic islets that can be detected by SSTR2-based in-vivo imaging, and have successfully treated tumor-bearing mice with PRRT. In addition, a recently developed xenograft model of PanNET has been established that can be detected with 68Ga-DOTA-TATE and harbors an MEN1 mutation.
Additional Details
- State: NY
- Grant Duration: 2 years
- Grant Partner: North American Neuroendocrine Tumor Society (NANETS)
- Awards: NETRF/NANETS Basic/Translational Science Investigator Award
DISCLAIMER
NETRF funds laboratory research to understand the development of neuroendocrine tumors and translational research to explore new concepts in treatment. Research grant descriptions and research updates from NETRF are not intended to serve as medical advice. It can take years for research discoveries to be fully validated and approved for patient care. Always consult your health care providers about your treatment options.